SKLB610 | 2610

SKLB610 is a VEGFR inhibitor that potently suppresses human tumor angiogenesis. SKLB610 inhibits angiogenesis-related tyrosine kinase VEGFR2, fibroblast growth factor receptor 2 (FGFR2) and platelet-derived growth factor receptor (PDGFR) at rate of 97%, 65% and 55%, respectively, at concentration of 10 μM in biochemical kinase assays.SKLB610 exhibits its antitumor activity as a multi-targeted inhibitor with more potent inhibition of VEGFR2 activity.

SKLB610 is a VEGFR inhibitor that potently suppresses human tumor angiogenesis. SKLB610 inhibits angiogenesis-related tyrosine kinase VEGFR2, fibroblast growth factor receptor 2 (FGFR2) and platelet-derived growth factor receptor (PDGFR) at rate of 97%, 65% and 55%, respectively, at concentration of 10 μM in biochemical kinase assays.

2610 | SKLB610 DataSheet

Alternate Name/Synonyms: N-Methyl-4-(4-(3-(trifluoromethyl)benzamido)phenoxy)picolinamide

Appearance: White solid

Formulation: N/A

CAS Number: 1125780-41-7

Structure Available?: Y

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₁H₁₆F₃N₃O₃

Molecular Weight: 415.36

Cell-Permeable?: Yes

Purity: >98% by HPLC

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent angiogenesis inhibitor

MDL Number: N/A

PubChem CID: N/A

SMILES: O=C(NC1=CC=C(OC2=CC=NC(C(NC)=O)=C2)C=C1)C3=CC=CC(C(F)(F)F)=C3

InChi: InChI=1S/C21H16F3N3O3/c1-25-20(29)18-12-17(9-10-26-18)30-16-7-5-15(6-8-16)27-19(28)13-3-2-4-14(11-13)21(22,23)24/h2-12H,1H3,(H,25,29)(H,27,28)

InChi Key: WACDHHMEVMSODJ-UHFFFAOYSA-N